Ramelteon:滥用催眠缺乏责任和镇静剂的不利影响。
文章的细节
-
引用
复制到剪贴板 -
约翰逊兆瓦,休斯PE、格里菲斯RR
Ramelteon:滥用催眠缺乏责任和镇静剂的不利影响。
拱创精神病学。2006年10月,63 (10):1149 - 57。
- PubMed ID
-
17015817 (在PubMed]
- 文摘
-
背景:Ramelteon是小说MT1是褪黑素受体选择性受体激动剂最近批准用于治疗失眠。大多数批准失眠药物滥用潜力和引起运动和认知障碍。目的:评估潜在的滥用,主观影响,电机和cognitive-impairing ramelteon而三唑仑的影响,一个典型的苯二氮卓类药物镇静催眠药物。设计:在这项双盲交叉研究中,每个参与者接受口服剂量的ramelteon(80,或160毫克)、三唑仑(0.25、0.5或0.75毫克),和安慰剂在大约18天。所有的参与者收到治疗分别在不同的日子。大部分措施评估结果在0.5小时药品管理局和反复药物管理局后24小时。设置:住宅研究设施。参与者:十四岁成年人的历史滥用镇静剂。主要结果测量:Subject-rated措施包括项目相关的潜在的滥用(如毒品喜欢、市值和药理分类),以及评估的范围广泛的兴奋剂和镇静剂的主观效果。Observer-rated措施包括评估的镇静和障碍。 Motor and cognitive performance measures included psychomotor and memory tasks and a standing balance task. RESULTS: Compared with placebo, ramelteon (16, 80, and 160 mg) showed no significant effect on any of the subjective effect measures, including those related to potential for abuse. In the pharmacological classification, 79% (11/14) of subjects identified the highest dose of ramelteon as placebo. Similarly, compared with placebo, ramelteon had no effect at any dose on any observer-rated or motor and cognitive performance measure. In contrast, triazolam showed dose-related effects on a wide range of subject-rated, observer-rated, and motor and cognitive performance measures, consistent with its profile as a sedative drug with abuse liability. CONCLUSION: Ramelteon demonstrated no significant effects indicative of potential for abuse or motor and cognitive impairment at up to 20 times the recommended therapeutic dose and may represent a useful alternative to existing insomnia medications.